Finance

Lists
RDY:NYSE
Dr Reddy's Laboratories Ltd
$14.13
-0.28%
(-0.040) 1D
$14.13
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RDY...
Open
$14.15
High
$14.20
Low
$14.05
Mkt. cap
11.80B
Avg. vol.
3.22M
Volume
1.93M
Dividend
0.59%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
39.91
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.35
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
Open
$14.15
High
$14.20
Low
$14.05
Mkt. cap
11.80B
Avg. vol.
3.22M
Volume
1.93M
Dividend
0.59%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
39.91
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.35
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Analyst ratings
Based on 3 analysts giving stock ratings to RDY in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RDY in the last 3 months.
Highest
Current $14.13
$14.80 (+4.74%)
Average
$14.35 (+1.56%)
Lowest
$13.90 (-1.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Neha Manpuria
Bank of America Securities
Buy
Maintained
-
-
10/26/2026
Alok Dalal
Jefferies
Hold
Upgraded
₹1,320.00
+9,241.8%
10/25/2026
Tausif Shaikh
Exane BNP Paribas
Buy
Upgraded
$14.80
+4.7%
10/12/2026
Unknown Analyst
Citi
Sell
Maintained
-
-
04/23/2026
Last report
Oct 23, 2026
Fiscal period
Q2 2027
₹11.21 / ₹8.87
+26.38%beat
Revenue / Est. (INR)
86.71B / 86.00B
+0.82%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
87.27B
75.16B
80.70B
86.71B
Cost of goods sold
40.46B
41.47B
43.16B
41.50B
Cost of revenue
40.46B
41.47B
43.16B
41.50B
Research and development expenses
6.15B
5.46B
5.77B
5.24B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.92B
27.76B
28.82B
28.08B
Operating expense
32.48B
32.53B
34.11B
32.44B
Total operating expenses
72.94B
74.00B
77.27B
73.94B
Operating income
14.33B
1.16B
3.43B
12.77B
Other non operating income
570.00M
512.00M
-
128.00M
EBT including unusual items
15.43B
1.99B
5.53B
12.28B
EBT excluding unusual items
15.52B
1.82B
4.09B
12.36B
Income tax expense
3.53B
-214.00M
1.18B
3.14B
Effective tax rate
22.90%
-10.75%
21.32%
25.60%
Other operating expenses
-591.00M
-693.00M
-477.00M
-875.00M
Net income
12.10B
2.20B
4.44B
9.25B
Net profit margin
13.86%
2.93%
5.50%
10.67%
Earnings per share
14.77
5.74
5.33
11.21
Interest and investment income
796.00M
890.00M
999.00M
961.00M
Interest expense
-944.00M
-1.06B
-1.26B
-1.25B
Net interest expenses
-148.00M
-167.00M
-256.00M
-287.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
19.54B
5.03B
8.80B
18.04B
Gain or loss from assets sale
-179.00M
-2.10B
-368.00M
-37.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps